|
Title
|
|
|
|
Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background: For reimbursement purposes of pimecrolimus cream 1%, the Belgian authorities asked to document its consumption, its topical corticosteroid-sparing effect and quality of life within the routine clinical practice. Objectives: We aimed to address the 3 queries of the Belgian authorities. Methods: An open-label, observational, multicentre, 1-year study under drug prescription was performed. Results: A total of 416 consecutive patients were enrolled in 49 centres. The mean annual amount of prescribed pimecrolimuscream 1% per patient was 120.8 g (SD = 117.0), with an estimated consumption of 104.4 g (SD = 117.6). The median annual amount prescribed was 90.0 g [interquartile range (IQR) = 45150] and the estimated consumption 63.6 g (IQR = 32.4132). Topical corticosteroids had been used before the study in 81.7% of the population. With pimecrolimus cream 1% during the study, 83.3% of the previous corticosteroid users stated less topical corticosteroid use than before and 36% of them did not apply topical corticosteroids at all during the study. The mean improvements compared to baseline in Parents Index Quality of Life-Atopic Dermatitis and Quality of Life Index-Atopic Dermatitis scores were 34.5% (SD = 84.3) and 31.2% (SD = 70.8), respectively. The median improvements were 50.0% (IQR = 12.585.7%) and 46.4% (IQR = 0.085.0%), respectively. Conclusions: In routine practice the consumption of pimecrolimus cream 1% is relatively low, with corticosteroid-sparing effect, improvement in quality of life and good tolerability. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Dermatology. - Basel
| |
|
Publication
|
|
|
|
Basel
:
2008
| |
|
ISSN
|
|
|
|
1018-8665
| |
|
DOI
|
|
|
|
10.1159/000136654
| |
|
Volume/pages
|
|
|
|
217
:2
(2008)
, p. 156-163
| |
|
ISI
|
|
|
|
000257516100013
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|